An analysis of a new drug’s journey to market, published today in the BMJ, shines a light on financial practices that see some major pharmaceutical companies relying on a cycle of acquisitions, profits from high prices, and shareholder-driven manoeuvres that threatens access to medicines for current and future patients.
Lawrence King (Department of Sociology) and Piotr Ozieranski (University of Bath) discuss how EU member states use complex policy instruments to determine how much they are willing to pay the pharmaceutical industry for its products.
GSK, the University of Cambridge and Cambridge University Hospitals NHS Foundation Trust today announce their Strategic Partnership, with the long-term ambition to jointly deliver new medicine to patients in the next 5-10 years.
Cambridge researchers and pharma in innovative new consortium to develop and study early stage drugs28 Jul 2015
An innovative new Consortium will act as a ‘match-making’ service between pharmaceutical companies and researchers in Cambridge with the aim of developing and studying precision medicines for some of the most globally devastating diseases.
Scientists report a new method for establishing whether chemical compounds are safe for human use without "in vivo" testing, based on so-called "molecular initiating events" at the boundary between chemistry and biology.